• The primary endpoint is FEV1 postdose response at Visit 3/week 8 (Day 58?2), end of the observation, vs. baseline (Visit 1/week 0 (Day 1 / baseline). [ Time Frame: 8 Weeks ]
  

• FVC postdose response at week 8 vs. baseline [ Time Frame: 8 Weeks ]
  
• IC postdose response at week 8 vs. baseline on the selected Sites [ Time Frame: 8 weeks ]
  
• Patient Global Assessment of efficacy and tolerability with 4 point scale symptoms at V3 [ Time Frame: 8 weeks ]
  
• Physician Global Assessment [ Time Frame: 8 weeks ]
  

Drug: tiotropium-bromide
Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care

The objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety of Spiriva (18 mcg tiotropium inhalation capsules) delivered by HandiHaler, in national sample of Russian patients with varying severities of hronic obstructive pulmonary disease (COPD) in the real life setting over the 8 weeks.

Study Hypothesis:

Primary interest is given to observe change from baseline in post-dose FEV1 after 8 weeks.

Comparison(s):

The objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety of Spiriva (18 mcg tiotropium inhalation capsules) delivered by HandiHaler, in national sample of Russian patients with varying severities of chronic obstructive pulmonary disease (COPD) in the real life setting over the 8 weeks.

Inclusion Criteria:

1. 40 years and older male and female ambulatory outpatients being seen in a participating physicians office for routine care
2. Patients not prior treated with the Tiotropium
3. Patients with clinical diagnosis of all stages of Chronic Obstructive Pulmonary Disease according to the current National Guidelines / 2004,2
4. Current smokers or ex-smokers with a smoking history 10 pack years

Exclusion Criteria:

1. Uncooperative patients as judged by the physician,
2. Patients that have any condition which, according to the participating physicians opinion, might decrease the chance of obtaining satisfactory data to achieve the objectives of the observation,
3. Patients with history of known preexisting or concomitant non-obstructive lung disease (e.g., sarcoidosis, tuberculosis, lung cancer),
4. Patients currently enrolled in another clinical trial which requires a change in medication for their respiratory problems,
5. Patients with any conditions listed in special precautions, drug interactions, and contraindication of Spirivas Russian package insert, such as:
6. Patients with known narrow-angle glaucoma,
7. Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction,
8. Patient with known moderate to severe renal impairment (creatinine clearance less than 50 ml/min),
9. Patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium or to any component of this product,
10. Pregnant or nursing women.